



# BioDtech, Inc. Company Profile

---

## Company Overview:

BioDtech, Inc. (BDTI) was formed to develop technologically advanced products for the endotoxin market. Based on the opportunity of existing, patented technology, BDTI negotiated a license agreement with the National University of Singapore (NUS) for exclusive worldwide licensing rights to develop endotoxin elimination and removal research products and technology. BDTI's current product line gives researchers the necessary reagents to detect, eliminate and remove endotoxin from their test samples.

**Corporate Mission:** To develop and market high quality, innovative products for the detection, neutralization and removal of biological toxins for the research and clinical markets.

## Corporate Objectives:

- Develop a rapid user-friendly system to measure endotoxin
- Design systems for the removal of toxins from aqueous solutions and whole blood
- Invent new therapeutic antibiotics based on existing, patented technology

## Technology:

The Factor C sushi peptide technology discovered by NUS offers several advantages over the current Limulus Amoebocyte Lysate (LAL) or recombinant Factor C (rFC) assay for endotoxin. It is a chemically synthesized peptide which reduces lot-to-lot variability associated with LAL or rFC. Factor C allows for a board range of assay conditions: salt concentration, no co-factors, temperature, pH and time. This should permit us to develop assays which are rapid, more accurate with fewer inhibition and enhancement problems. Factor C binding based assays will open new markets: environmental, industrial and medical hygiene, military and clinical, which have been limited by the enzymatic nature of LAL and rFC. The sushi peptide is also an antimicrobial which neutralizes endotoxin. This could be a new class of antibiotic which rapidly kills gram-negative bacteria and eliminates the affect of endotoxin at the same time.

## Current Target Markets:

- Bioresearch
- Bioprocessing
- Clinical testing

## Therapeutic Markets:

- Sepsis
- Cystic Fibrosis
- AIDS
- Wound care
- Eye care

**Incorporated:** September 2003 (State of Delaware "C Corp")

**Employees:** 6

## Corporate Headquarters:

3200 West End Avenue, Suite 500  
Nashville, TN 37203  
Phone: 615-783-1708  
Fax: 615-783-1606

**Leadership:** Michael Pepe, PhD, CEO/President, Ira Weiss, VP of Finance and Operations

**Partners:** National University of Singapore (NUS)

**Commercial Partners:** We are currently seeking partners to further the development of endotoxin assays and therapeutic applications on a global basis.

---